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Abstract
Introduction We have demonstrated in a multicenter cohort that the COVID-19 pandemic has led to a delay in intravenous 
thrombolysis (IVT) among stroke patients. Whether this delay contributes to meaningful short-term outcome differences in 
these patients warranted further exploration.
Methods We conducted a nested observational cohort study of adult acute ischemic stroke patients receiving IVT from 9 
comprehensive stroke centers across 7 U.S states. Patients admitted prior to the COVID-19 pandemic (1/1/2019–02/29/2020) 
were compared to patients admitted during the early pandemic (3/1/2020–7/31/2020). Multivariable logistic regression was 
used to estimate the effect of IVT delay on discharge to hospice or death, with treatment delay on admission during COVID-
19 included as an interaction term.
Results Of the 676 thrombolysed patients, the median age was 70 (IQR 58–81) years, 313 were female (46.3%), and the 
median NIHSS was 8 (IQR 4–16). Longer treatment delays were observed during COVID-19 (median 46 vs 38 min, p = 0.01) 
and were associated with higher in-hospital death/hospice discharge irrespective of admission period (OR per hour 1.08, 
95% CI 1.01–1.17, p = 0.03). This effect was strengthened after multivariable adjustment (aOR 1.15, 95% CI 1.07–1.24, 
p < 0.001). There was no interaction of treatment delay on admission during COVID-19 (pinteraction = 0.65). Every one-hour 
delay in IVT was also associated with 7% lower odds of being discharged to home or acute inpatient rehabilitation facility 
(aOR 0.93, 95% CI 0.89–0.97, p < 0.001).
Conclusion Treatment delays observed during the COVID-19 pandemic led to greater early mortality and hospice care, with 
a lower probability of discharge to home/rehabilitation facility. There was no effect modification of treatment delay on admis-
sion during the pandemic, indicating that treatment delay at any time contributes similarly to these short-term outcomes.
Keywords Stroke · COVID-19 · Thrombolysis · Treatment delay · Outcomes · Mortality
Introduction
The coronavirus disease 2019 (COVID-19) pandemic has 
had a deleterious impact on health care systems across the 
world. In addition to its direct neurological manifestations, 
notable indirect effects pertain to the delays in presenta-
tion and management of emergent medical conditions like 
myocardial infarction, and stroke [1–3]. Recent studies have 
also shown declines in stroke admissions during the pan-
demic, but with limited data on its impact on stroke manage-
ment metrics and their related outcomes [4].
Delays in thrombolysis are associated with poor clini-
cal outcomes with a large registry study involving 55, 296 
ischemic stroke patients showing higher odds of in-hospital 
mortality associated with such delays [5]. Our recently pub-
lished multicenter study involving high-volume stroke cent-
ers across the U.S showed significantly greater delays in rep-
erfusion therapy with intravenous thrombolysis (IVT) during 
the early pandemic period compared to the pre-pandemic 
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period [6]. We aimed to elucidate the impact of such delays 
on early neurological outcomes.
Methods
A nested cohort study of patients who received IVT and had 
completed data regarding door-to-needle time and sympto-
matic intracranial hemorrhage (sICH) within 36 h was con-
ducted using a previously described observational registry 
[4, 6]. Patients with stroke admitted prior to the COVID-19 
pandemic (1/1/2019–02/29/2020) were compared to patients 
admitted during the early pandemic (3/1/2020–7/31/2020). 
In addition to the variables previously described [4, 6], sICH 
was collected from participating registries and defined as 
any clinical worsening attributed to an intracranial hemor-
rhage that occurred within 36 h of thrombolysis [7]. Based 
on completeness of data for this subgroup analysis, consecu-
tive acute ischemic stroke patients admitted to 9 Compre-
hensive Stroke Centers in 7 U.S. states were screened for 
inclusion. Patients were excluded if they were not treated 
with IVT, if they had unavailable door-to-needle times, or 
incomplete documentation of sICH. None of the participat-
ing sites in this analysis utilized a mobile stroke unit. Data 
will be made available upon reasonable request of a qualified 
investigator with the approval of the local regulatory board.
Descriptive statistics were used to summarize differences 
in key clinical, management, and outcome variables. Cat-
egorical variables are expressed as proportions and were 
compared between study periods using the Chi-square test, 
and non-normally distributed continuous variables as medi-
ans with interquartile range, with differences assessed using 
the Wilcoxon Rank-Sum test.
The pre-specified primary outcome was a composite of 
discharge to hospice or in-hospital mortality, which was 
defined as an unfavorable disposition. The secondary out-
come was a favorable discharge disposition (composite of 
discharge to home or an acute inpatient rehabilitation facil-
ity [IRF]). Unadjusted linear and logistic regression models 
were used to estimate the effect of covariates on the primary 
outcome measure. All variables significant to p < 0.1 were 
then entered into two multivariable logistic regression mod-
els—one with a multiplicative interaction term of treatment 
delay on COVID-19 period, and one without the interaction 
term. The performance of each model was assessed using 
the Akaike Information Criterion (AIC). A multivariable 
regression model was also generated to estimate the effect 
of delay in door-to-needle time on the secondary outcome 
(favorable disposition). This model was derived using the 
aforementioned technique, with the inclusion of the interac-
tion term (treatment delay × COVID-19). Exploratory sub-
group analyses were used to confirm the effect of treatment 
delay on death/hospice irrespective of admission prior to 
(n = 537) or during COVID-19 (n = 139) using multivariable 
logistic regression after adjusting for variables significant 
to p < 0.1 in univariate regression, as detailed above. All 
multivariable models were clustered by site.
Missing data were not imputed. All tests were two-sided 
with a significance level set at 0.05. No adjustments were 
made for multiple comparisons. P values are provided for a 
convention but should be interpreted with caution as analy-
ses were exploratory. All analyses were performed using 
STATA 15.0 (College Station, TX).
Results
Of the 6257 patients admitted during the study period, 
778 received IVT (12.4%). One hundred two patients were 
excluded due to unavailable door-to-needle times. Of the 676 
included, the median age was 70 (IQR 58–81), 313 (46.3%), 
were female, and the median NIHSS was 8 (IQR 4–16). The 
simplified demographic, treatment and clinical outcomes are 
summarized in Table 1.
There were 62 (9.1%) patients out of the 676 included 
with an unfavorable disposition of in-hospital death or dis-
charge to hospice during the study period. There was no 
significant increase in death or hospice discharge during 
COVID-19 when compared to the preceding period (10.1% 
vs. 8.9%, p = 0.68). A majority (73%) were discharged to a 
favorable disposition throughout the study period, with no 
difference across the two periods (69.8% [COVID-19] vs. 
74.1% [Pre-COVID-19], p = 0.30). Patients treated during 
COVID-19 had a median delay of 8 min from door-to-needle 
in comparison with the preceding period (median 46 [IQR 
29–64] vs. 38 [IQR 26–56], p = 0.01).
Primary outcome
In univariate analysis, age, white race, atrial fibrillation, 
heart failure, baseline NIHSS, door-to-needle time, and 
sICH were associated with in-hospital death or discharge to 
hospice (Table 2). Every hour delay in IVT was associated 
with 8% higher odds of death/hospice (OR per hour 1.08, 
95% CI 1.01–1.17, p = 0.03). In the multivariable logistic 
regression model, including all variables significantly asso-
ciated in univariate analysis, including an interaction term 
for treatment delay on COVID-19 period), the association 
between delay in IVT was strengthened, with every hour 
corresponding to 15% higher odds of discharge to hospice/
death (aOR 1.15, 95% CI 1.07–1.24, p < 0.001). There was 
no significant interaction between treatment delay and 
admission during the COVID-19 period on the outcome of 
death/hospice in this model (p = 0.65 for interaction). Model 
performance was similar with and without the interaction 
term (AIC 284.28 vs. 284.31). In subgroup analyses, after 
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multivariable adjustment and clustering by site, delays in 
IVT remained independently associated with higher odds 
of in-hospital mortality/hospice prior to the COVID-19 pan-
demic (aOR 1.17, 95% CI 1.06–1.28, p = 0.001) and during 
the pandemic (aOR 1.10, 95% CI 1.02–1.19, p = 0.017).
Secondary outcome
With regard to the secondary outcome of favorable discharge 
to home or IRF, in the univariate analysis, older age, female 
sex, atrial fibrillation, heart failure, NIHSS, door-to-needle 
time per hour and sICH (all negative predictors), along with 
tobacco use (positive predictor) were associated with dis-
charge to a favorable disposition of home or IRF. Longer 
delays to IVT remained associated with a non-significantly 
lower probability of discharge to a favorable discharge dis-
position (OR per hour 0.95, 95% CI 0.89–1.007, p = 0.089). 
In multivariable model, including all variables significantly 
associated with favorable discharge in univariate regres-
sion, and clustering by site, every one-hour delay in IVT 
was associated with a 7% reduction in the odds of being 
discharged to home or IRF (aOR 0.93, 95% CI 0.89–0.97, 
p < 0.001).
Discussion
In this follow-up investigation to a prior analysis which 
established that patients admitted during COVID-19 are 
treated more slowly with thrombolysis, [6] we now confirm 
that these delays in treatment are independently associated 
with worse short-term outcomes. Importantly, there was 
no modification of this effect by the period in which treat-
ment was administered—e.g., treatment delays were asso-
ciated with similarly higher short-term mortality/hospice 
rates irrespective of the treatment period (COVID-19 vs. 
pre-COVID-19). Moreover, the strength of the association 
improved after adjustment for clinically important, measura-
ble confounders. Together, these data indicate that treatment 
delays during COVID-19, rather than any significant effect 
of the COVID-19 period itself, are important contributors to 
early adverse outcomes of stroke patients treated during the 
pandemic. Although we did not find a significant difference 
Table 1  Demographic and 
clinical differences between 
study periods
IQR denotes interquartile range, NIHSS National Institutes of Health Stroke Scale, and sICH symptomatic 






Age, median y (IQR) 71 (59–82) 68 (57–77) 0.05
Female sex, no. (%) 251 (46.7%) 62 (44.6%) 0.65
Race, no. (%)  < 0.01
 White 412 (76.7%) 88 (63.3%)
 Black 88 (16.4%) 40 (28.8%)
 Other/unknown 37 (6.9%) 11 (7.9%)
Hispanic ethnicity, no. (%) 180 (33.5%) 42 (30.2%) 0.46
Transfer from outside hospital, no. (%) 13 (3.0%) 8 (6.0%) 0.11
Past medical history, no. (%)
 Hypertension 417 (77.7%) 88 (63.3%)  < 0.01
 Dyslipidemia 293 (54.6%) 74 (53.2%) 0.78
 Diabetes 186 (34.6%) 44 (31.7%) 0.51
 Coronary artery disease 99 (18.4%) 24 (17.3%) 0.75
 Prior ischemic stroke 95 (17.7%) 32 (23.0%) 0.15
 Atrial fibrillation 93 (17.3%) 27 (19.2% 0.56
 Tobacco use 69 (12.9%) 19 (13.7%) 0.80
 Heart failure 54 (10.1%) 20 (14.4%) 0.15
NIHSS, median (IQR) 8 (4–16) 10 (5–17) 0.16
Proximal large vessel occlusion, no. (%) 127 (23.7%) 35 (25.2%) 0.71
 Thrombectomy, no. (%) 106/127 (83.5%) 29/35 (82.9%) 0.93
Door-to-needle, median min. (IQR) 38 (26–56) 46 (29–64) 0.01
sICH 23 (4.3%) 6 (4.3%) 0.99
In-hospital death/discharge to hospice, no. (%) 48 (8.9%) 14 (10.1%) 0.68
Discharge to home/acute rehab, no. (%) 398 (74.1%) 97 (69.8%) 0.30
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in discharge to hospice or in-hospital death among patients 
admitted before or during the COVID-19 pandemic, as we 
have shown in a prior analysis with greater statistical power, 
[6] these treatment delays occurred more frequently during 
the pandemic. Therefore, one may deduce that the greater 
treatment delays during the pandemic are contributing to 
worse outcomes among patients treated during this period.
The relationship between time and brain has been well 
characterized, [8] and our study confirms that even small 
treatment delays can lead to significant short-term conse-
quences for these patients [6]. Identification of the specific 
stroke workflow components that could potentially impact 
such delays associated with reperfusion therapy would be 
crucial in improving the stroke metrics and their associated 
outcomes. Delays in arrival to imaging as was seen in a 
study by Wu et al. could be contributory although inter-
estingly the same effect was not seen in our study and a 
few others [9–11]. This could be postulated in part due to 
the drastic reduction of imaging modality use during the 
pandemic period with almost 39% reduction as was noted 
in a study by Kansagra et al. that possibly led to increased 
resource availability and resulting efficiency [12]. In this 
setting, delays from imaging to thrombolysis, are the pri-
mary area of contention that are yet to be elucidated, and 
the major factors associated with treatment delays overall. 
Future studies targeting the imaging to thrombolysis com-
ponent of acute stroke workflows might play a vital role in 
helping reduce treatment delays and thereby improve out-
comes in this continuing pandemic.
Limitations
Although the effect estimate of our findings and the perfor-
mance of our models were robust, our study remains limited 
by its retrospective nature and small sample size. It is possi-
ble that the small sample size may have contributed to a type 
II error in our assessment of the interaction between treat-
ment delay and the COVID-19 admission period. We have 
previously shown that small, but non-significant increases 
in-hospital mortality among stroke patients admitted dur-
ing COVID-19 are likely mediated by a greater severity 
of the stroke [13]. It remains possible that admission dur-
ing COVID-19 may be an independent risk factor for early 
mortality and unfavorable short-term outcomes. Larger 
Table 2  Unadjusted and 
adjusted regression model for 
in-hospital death or discharge 
to hospice
OR denotes odds ratio (with 95% confidence interval), COVID-19 coronavirus disease 2019, NIHSS 
National Institutes of Health Stroke Scale, and sICH symptomatic intracerebral hemorrhage within 36 h of 
thrombolysis
a Final multivariable model shown is inclusive of the interaction term for treatment delay on admission dur-
ing the COVID-19 period (AIC 284.28)
b sICH was defined using NINDS criteria as any neurologic worsening attributed to an intracranial hemor-
rhage which occurred within 36 h of thrombolysis
Unadjusted regression model Adjusted regression  modela
OR (95% CI) p value OR (95% CI) p value
COVID-19 admission 0.88 (0.47–1.64) 0.68
Door-to-needle, per hour 1.08 (1.01–1.17) 0.03 1.15 (1.07–1.24)  < 0.001
Door-to-needle × COVID-19 period 0.97 (0.83–1.13) 0.65
Age, per decade 1.72 (1.39–2.12)  < 0.001 1.35 (1.11–1.64)  < 0.001
Female sex 1.36 (0.80–2.29) 0.25
White race 2.20 (1.06–4.56) 0.03 2.09 (0.98–4.45) 0.056
Hispanic ethnicity 0.97 (0.56–1.70) 0.92
Transfer from outside hospital 1.14 (0.26–5.03) 0.87
Hypertension 1.07 (0.58–1.96) 0.83
Dyslipidemia 1.02 (0.61–1.73) 0.93
Diabetes 1.07 (0.62–1.85) 0.80
Coronary artery disease 1.35 (0.72–2.54) 0.35
Prior ischemic stroke 1.16 (0.61–2.22) 0.65
Atrial fibrillation 3.14 (1.80–5.50)  < 0.001 1.22 (0.75–1.99) 0.41
Tobacco use 0.44 (0.15–1.23) 0.12
Heart failure 2.14 (1.08–4.23) 0.03 1.77 (0.65–4.82) 0.27
NIHSS, per point 1.15 (1.11–1.19)  < 0.001 1.15 (1.12–1.17)  < 0.001
Large vessel occlusion 1.58 (0.90–2.78) 0.11
sICHb 8.43 (3.81–18.63)  < 0.001 8.06 (4.14–15.70)  < 0.001
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observational studies or pooling of published cohorts may 
reveal this association. Our study is also limited by the lack 
of available data regarding concomitant COVID-19 diagno-
ses among patients admitted during the COVID-19 period, 
which could have also contributed to higher mortality/
hospice during the COVID-19 period. That said, infection 
rates among all consecutively hospitalized stroke patients 
are < 5%, and while mortality is high among COVID-19 
stroke patients (~ 20–40%), the overall small proportion of 
COVID-19 stroke patients is not likely to contribute mean-
ingfully to the present analysis [6]. Further, there was no 
significant increase in mortality/hospice in this nested cohort 
study.
Conclusion
The data from our study indicate that stroke treatment delays 
during the COVID-19 pandemic can lead to significant 
short-term consequences for stroke patients. Because treat-
ment delays appear more common during the COVID-19 
period, stroke centers should evaluate local practice para-
digms to expedite the acute care of stroke patients during 
COVID-19—and any crisis for that matter— to reduce the 
odds of short-term unfavorable outcomes.
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